FCγ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical RelevanceSara Caratelli, Giuseppe Sconocchia, Tommaso Sconocchia et al.|Frontiers in Immunology|2017Cited by 75
<i>In vitro</i> elimination of epidermal growth factor receptor‐overexpressing cancer cells by CD32A‐chimeric receptor T cells in combination with cetuximab or panitumumabSara Caratelli, Giuseppe Sconocchia, Roberto Arriga et al.|International Journal of Cancer|2019Cited by 43
CD16‐158‐valine chimeric receptor T cells overcome the resistance of KRAS‐mutated colorectal carcinoma cells to cetuximabRoberto Arriga, Giuseppe Sconocchia, Mario Roselli et al.|International Journal of Cancer|2019Cited by 28
Recent perspective on CAR and Fcγ-CR T cell immunotherapy for cancers: Preclinical evidence versus clinical outcomesHany E. Marei, Giuseppe Sconocchia, Asma Al-Thani et al.|Biochemical Pharmacology|2019Cited by 25
Natural humoral immune response to ribosomal P0 protein in colorectal cancer patientsMonica Benvenuto, Roberto Bei, Pierpaolo Sileri et al.|Journal of Translational Medicine|2015Cited by 21